RUA Life Sciences
RUA · AIM · Health Care · mcap £14m · 23.0p 1 open situation →
Briefing
New to RUA Life Sciences? Get up to speed in 2 minutes.
What it does, how it got here, what management promised and delivered, where it stands now – written from its own announcements, every line linked to its source.
Free · we write the most-requested ones first.
Timeline · every situation
dots = announcementsOpen · 1
Disposal of a part (break-up)◷ in 415 days
ABISS product transfer MOU
Spun out, deconsolidated; testing planned 2027
RUA Structural Heart was spun out during the year to 30 Sep 2026 with £3m of external convertible loan funding and £4.8m of intercompany balances capitalised. It is no longer consolidated, producing a non-recurring gain of about £4.8m. Testing planned during 2027 could be a value inflection point.
- External funding
- £3 million convertible loan 9 Nov 2026 ↗
- Intercompany
- £4.8 million of balances capitalised 9 Nov 2026 ↗
- Accounting gain
- Non-recurring gain of approximately £4.8 million on loss of control 9 Nov 2026 ↗
- Cost to RUA pre spin-out
- £0.2 million 9 Nov 2026 ↗
- Next milestone
- Animal studies on novel AurTex leaflet valve design during 2027 9 Nov 2026 ↗
Next: animal studies on novel valve design · 31 Dec 2027
- 9 Nov 2026 MOU agreed with customer
Closed · 1
Company filings. Not investment advice.